Clinical Trial

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemotherapy-navïe for their extensive-stage disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-03-01; most recent amendment 2026-04-23.
Status change: Recruiting → Active, Not Recruiting 2026-04-23
Status change: Not Yet Recruiting → Recruiting 2024-04-15
Trial Details
NCT Number NCT05765825
Lead Sponsor Sichuan University
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 61 participants
Start Date 2023-03-07
Primary Completion 2024-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29